PCAST Working Group, Co-Led by PSMF Founder Joe Kiani, Releases Report on Transforming Patient Safety
8.9.2023 04:43:00 EEST | Business Wire | Press release
The President’s Council of Advisors on Science and Technology (PCAST) released its findings and recommendations on patient safety in a report to U.S. President Joe Biden. Titled “A Transformational Effort on Patient Safety,” the report also outlines the many ways that “patient safety is an urgent national public health issue.” The distinguished PCAST Working Group on Patient Safety is co-led by the founder of the Patient Safety Movement Foundation, Joe Kiani, and Microsoft’s Chief Scientific Officer, Eric Horvitz.
The PCAST report to the Biden-Harris administration pointed out that according to recent data, “Medicare patients suffer an adverse event in one out of four hospitalizations, and one third of those adverse events are serious, including catastrophic outcomes,” and that “adverse outcomes disproportionately impact people from groups historically experiencing social marginalization, widening gaps in healthcare disparities.”
“Preventable medical errors take hundreds of thousands of lives each year. I am optimistic that these recommendations will help fast-track solving this critical problem that destroys so many lives,” said Joe Kiani, co-leader of the PCAST Working Group on Patient Safety. “It was an honor to work with such a distinguished cohort of fellow PCAST committee members on what we believe is an urgent mission, and I am grateful for everyone’s contributions. I know President Biden has been waiting for this report. He is our country’s biggest patient advocate and cares deeply about the very real suffering that happens every day across the U.S. healthcare systems due to medical errors.”
“This is a major milestone in healthcare safety in the United States, and if implemented, we believe it will influence and improve patient safety and healthcare worker safety around the world. Since our inception, we understood that for long-lasting change to happen, it would require direction from the highest levels of government. These recommendations could not have come at a better time because WHO’s World Patient Safety Day is on September 17th,” said Dr. Michael Ramsay, CEO of the Patient Safety Movement Foundation.
The report acknowledges that despite significant efforts made by many healthcare workers and organizations to reduce preventable medical errors by implementing evidence-based safety protocols, nationwide implementation of many of these known solutions has lagged. The report then outlines four recommendations to “advance health equity, improve the nation’s health and well-being, and avert suffering and death for hundreds of thousands of Americans each year.” The recommendations are as follows:
Recommendation 1: Establish and Maintain Federal Leadership for the Improvement of Patient Safety as a National Priority.
1.A Appoint a Patient Safety Coordinator Reporting to the President on Efforts to Transform Patient Safety Among All Relevant Government Agencies.
1.B Establish a Multidisciplinary National Patient Safety Team (NPST) and Ensure Inclusion of Persons from Populations Most Affected.
Recommendation 2: Ensure That Patients Receive Evidence-Based Practices for Preventing Harm and Addressing Risks.
2.A Identify and Address High-Priority Harms and Promote Patient Safety Though Incentivizing the Adoption of Evidence-Based Solutions and Requiring Annual Public Reporting Immediately and Quarterly Public Reporting Within 5 Years.
2.B Create a Learning Ecosystem and Shared Accountability System to Ensure That Evidence-Based Practices are Implemented and Goals for Reduced Harms and Risks of Harm for Every American are Realized.
2.C Advance Interoperability of Healthcare Data and Assure Access to the Tracking of Harms and Use of Evidence-Based Solutions.
2.D Improve Safety for All Healthcare Workers and Their Patients Through Supporting a Just Culture of Patient and Clinician Safety in Healthcare Systems.
Recommendation 3: Partner with Patients and Reduce Disparities in Medical Errors and Adverse Outcomes.
3.A Implement a “Whole of Society Approach” in the Transformational Effort on Patient Safety.
3.B Improve Data and Transparency to Reduce Disparities.
Recommendation 4: Accelerate Research and Deployment of Practices, Technologies, and Exemplar Systems of Safe Care.
4.A Develop a National Patient Safety Research Agenda.
4.B Harness Revolutionary Advances in Information Technologies.
4.C Develop Federal Healthcare Delivery Systems’ Capacities and Showcase Results as Exemplars for Safer Healthcare.
PCAST is a federal advisory committee appointed by the U.S. president to augment the science and technology advice available to him. PCAST consists of 28 of the nation’s thought leaders, selected for their distinguished service and accomplishments in academia, government, and the private sector. Joe Kiani, who founded the Patient Safety Movement Foundation (PSMF) in 2012 and served for many years as its first chair, was appointed to PCAST in September 2021. Also serving with Kiani and Horvitz in the PCAST patient safety working group are:
- Donald Berwick, MD, Patient safety expert, CMS, Institute for Healthcare Improvement
- Lisa Cooper, Johns Hopkins University
- Sue Desmond-Hellmann, Former CEO, Gates Foundation, Former Chancellor UCSF
- Christopher Hart, Safety systems expert, National Transportation Safety Board
- Harlan Krumholz, MD, Outcomes research pioneer, Yale University
- Julie Morath, RN, Patient safety expert, Hospital Quality Institute
- Peter Pronovost, MD, Patient safety expert, University Hospitals Cleveland Medical Center
- Sue Sheridan, Patient advocate, Patients for Patient Safety
ABOUT THE PATIENT SAFETY MOVEMENT FOUNDATION
In 2012, Joe Kiani founded the non-profit Patient Safety Movement Foundation (PSMF) to eliminate preventable medical errors in hospitals. His team worked with patient safety experts from around the world to create Actionable Evidence-Based Practices (AEBP) that address the top challenges. The AEBP are available without charge to hospitals online. Hospitals are encouraged to make a formal commitment to ZERO preventable deaths, and healthcare technology companies are asked to sign the Open Data Pledge to share their data so that predictive algorithms that can identify errors before they become fatal can be developed. The Foundation's annual World Patient Safety, Science & Technology Summit brings together all stakeholders, including patients, healthcare providers, medical technology companies, government employers, and private payers. The PSMF was established through the support of the Masimo Foundation for Ethics, Innovation, and Competition in Healthcare. For more information, please visit psmf.org.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230907964291/en/
Contact information
Patient Safety Movement Foundation
Irene Mulonni, irene@mulonni.com | (858) 859-7001
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Zynyz ® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 16:29:00 EET | Press release
Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “Today’s positive CHMP opinion is an important step towards addressing the urgent need for new treatment options for patients in Europe with advanced SCAC, a disease which has seen limited innovation for decades,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved, Zynyz in combination with platinum-based chemotherapy has the potential to become a new standard-of-care for patients living with this rare and difficult-to-treat cancer.” The positive CHMP opinion was based on data from the Phase 3 POD1UM-303/Inter
Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 14:32:00 EET | Press release
Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,
BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 10:00:00 EET | Press release
With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerful, secure, reliable, and intelligent digital signage,” said Steve Durkee, chief executive office
Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 09:30:00 EET | Press release
Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, supported by one of the largest bodies of published clinical data backed by decades of clinica
Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 09:00:00 EET | Press release
Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets. “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.” Throughout his career, Dan has held senior leadership roles i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
